Dr. Fagan's research in pulmonary arterial hypertension revolves around several key projects all using animal models of PAH to better understand the pathophysiology of this fatal disease and identify potential new therapeutic targets. Dr. Fagan is also a clinician specializing in the treatment of patients with PAH at the University of South Alabama Pulmonary Hypertension Center. Current research projects including the role of inflammation in the pathogenesis of PAH, specifically the role of IL-6. Using transgenic animals that overexpress IL-6, we plan to investigate downstream signals and their role in promoting the development of PAH. In another project, the role of integrins (proteins that link the extracellular matrix to cells) and their role in controlling cellular functions in PAH (such as contraction) are also being investigated.
Expertise:
- Basic mechanisms and clinical pharmacology of pulmonary arterial hypertension
Expertise: Pulmonology: Pulmonary Diseases and Critical Care Medicine
